Jane Street Group LLC acquired a new position in shares of Beigene Ltd (NASDAQ:BGNE) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,276 shares of the company’s stock, valued at approximately $339,000.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Employees Retirement System of Texas bought a new stake in Beigene during the second quarter worth approximately $2,855,000. Alps Advisors Inc. increased its holdings in shares of Beigene by 15.9% in the third quarter. Alps Advisors Inc. now owns 41,739 shares of the company’s stock valued at $4,318,000 after buying an additional 5,732 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in shares of Beigene by 25.0% in the second quarter. Parametric Portfolio Associates LLC now owns 13,496 shares of the company’s stock valued at $607,000 after buying an additional 2,700 shares in the last quarter. Westpac Banking Corp bought a new position in shares of Beigene in the third quarter valued at $662,000. Finally, Baillie Gifford & Co. increased its holdings in shares of Beigene by 5.0% in the second quarter. Baillie Gifford & Co. now owns 74,424 shares of the company’s stock valued at $3,349,000 after buying an additional 3,559 shares in the last quarter. Institutional investors and hedge funds own 55.32% of the company’s stock.
Beigene Ltd (NASDAQ BGNE) traded up $0.17 during mid-day trading on Thursday, reaching $101.84. 160,125 shares of the company’s stock were exchanged, compared to its average volume of 186,003. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 9.27. Beigene Ltd has a one year low of $31.00 and a one year high of $118.95. The company has a market capitalization of $4,630.00 and a PE ratio of -77.74.
Beigene (NASDAQ:BGNE) last released its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million for the quarter, compared to the consensus estimate of $1.55 million. During the same quarter last year, the company earned ($1.08) earnings per share. equities analysts forecast that Beigene Ltd will post -2.04 earnings per share for the current fiscal year.
Several brokerages have issued reports on BGNE. Maxim Group set a $120.00 target price on shares of Beigene and gave the company a “buy” rating in a research note on Monday, December 18th. Cowen reissued a “buy” rating on shares of Beigene in a research note on Tuesday, November 14th. ValuEngine cut shares of Beigene from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Beigene from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, Zacks Investment Research cut shares of Beigene from a “hold” rating to a “sell” rating in a report on Monday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $96.67.
In related news, CMO Jane Huang sold 1,000 shares of the stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $98.00, for a total value of $98,000.00. Following the completion of the transaction, the chief marketing officer now owns 1,000 shares of the company’s stock, valued at $98,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Oyler sold 150,957 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the sale, the chief executive officer now directly owns 491,891 shares in the company, valued at $39,597,225.50. The disclosure for this sale can be found here. Insiders have sold 483,482 shares of company stock valued at $42,139,474 in the last ninety days. 19.90% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/jane-street-group-llc-buys-new-stake-in-beigene-ltd-bgne.html.
Beigene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.